FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB: NRGX) (the “Company”), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today its financial results for the third quarter and nine months ended September 30, 2009.
